MetaCap

Cingulate (CING) vs Medicinova (MNOV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cingulate (CING) has outperformed Medicinova (MNOV) over the past year, gaining 27.8% versus a loss of 8.4%. Cingulate is the larger company by market cap ($67.5 million vs $67.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CING+27.76%MNOV-8.39%
+243%+108%-26%
Nov 21, 20251 yearNov 20, 2026
CING-99.49%MNOV-57.33%
+14%-46%-105%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CING versus MNOV key metrics
MetricCINGMNOV
Share price$4.51$1.31
Market cap$67.48M$67.11M
1-day change-14.26%+3.15%
YTD return+3.92%0.00%
1-year return+27.76%-8.39%
5-year return—-59.32%
EPS (TTM)$-2.67$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$409.66K
Net income (latest FY)$-22.45M$-12.00M
Operating margin—-3242.47%
Net margin—-2928.78%
52-week high$11.89$3.90
52-week low$3.16$1.22
Distance from 52-week high-62.07%-66.41%
Analyst consensusnonestrong_buy
Avg. price target upside+370.07%+529.77%
Average volume178.82K334.96K
Shares outstanding14.96M51.23M
Employees146
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CING has outperformed MNOV by 36.2 percentage points over the past year.

About Cingulate

CING stock →

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Medicinova

MNOV stock →

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

CING vs MNOV FAQ

Which is bigger, Cingulate or Medicinova?

Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $67.11M for Medicinova (MNOV).

Which stock has performed better over the past year, CING or MNOV?

CING returned +27.76% over the past 12 months, compared with -8.39% for MNOV (price return, excluding dividends). Past performance does not predict future results.

Are Cingulate and Medicinova in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons